SINGULARITY OF CONTROLS IN A SIMPLE MODEL OF ACQUIRED CHEMOTHERAPY RESISTANCE

被引:12
作者
Bajger, Piotr [1 ]
Bodzioch, Mariusz [2 ]
Forys, Urszula [3 ]
机构
[1] Univ Warsaw, Interfac Individual Doctoral Studies Nat Sci & Ma, Banacha 2c, PL-02097 Warsaw, Poland
[2] Univ Warmia & Mazury, Fac Math & Comp Sci, Sloneczna 54, PL-10710 Olsztyn, Poland
[3] Univ Warsaw, Inst Appl Math & Mech, Fac Math Informat & Mech, Banacha 2, PL-02097 Warsaw, Poland
来源
DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B | 2019年 / 24卷 / 05期
关键词
Optimal control; ordinary differential equations; cancer chemotherapy; drug resistance; non-homogeneous tumour; CANCER-CHEMOTHERAPY; DRUG-RESISTANCE; HETEROGENEITY; EVOLUTION; GROWTH;
D O I
10.3934/dcdsb.2019083
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
This study investigates how optimal control theory may be used to delay the onset of chemotherapy resistance in tumours. An optimal control problem with simple tumour dynamics and an objective functional explicitly penalising drug resistant tumour phenotype is formulated. It is shown that for biologically relevant parameters the system has a single globally attracting positive steady state. The existence of singular arc is then investigated analytically under a very general form of the resistance penalty in the objective functional. It is shown that the singular controls are of order one and that they satisfy Legendre-Clebsch condition in a subset of the domain. A gradient method for solving the proposed optimal control problem is then used to find the control minimising the objective. The optimal control is found to consist of three intervals: full dose, singular and full dose. The singular part of the control is essential in delaying the onset of drug resistance.
引用
收藏
页码:2039 / 2052
页数:14
相关论文
共 21 条
[1]  
Bajger P., 2016, P 16 C COMP MATH MET, V1, P132
[2]   Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation [J].
Chisholm, Rebecca H. ;
Lorenzi, Tommaso ;
Clairambault, Jean .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2016, 1860 (11) :2627-2645
[3]   Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth [J].
Cho, H. ;
Levy, D. .
JOURNAL OF THEORETICAL BIOLOGY, 2018, 436 :120-134
[4]   Chemotherapeutic drugs - more really is not better [J].
Fidler, IJ ;
Ellis, LM .
NATURE MEDICINE, 2000, 6 (05) :500-502
[5]   Evolution of acquired resistance to anti-cancer therapy [J].
Foo, Jasmine ;
Michor, Franziska .
JOURNAL OF THEORETICAL BIOLOGY, 2014, 355 :10-20
[6]   Mechanisms of cancer drug resistance [J].
Gottesman, MM .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :615-627
[7]  
Hahnfeldt P, 1999, CANCER RES, V59, P4770
[8]   Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis [J].
Hahnfeldt, P ;
Folkman, J ;
Hlatky, L .
JOURNAL OF THEORETICAL BIOLOGY, 2003, 220 (04) :545-554
[9]   Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance [J].
Kareva, Irina ;
Waxman, David J. ;
Klement, Giannoula Lakka .
CANCER LETTERS, 2015, 358 (02) :100-106
[10]   The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance [J].
Lavi, Orit ;
Greene, James M. ;
Levy, Doron ;
Gottesman, Michael M. .
CANCER RESEARCH, 2013, 73 (24) :7168-7175